RT Journal Article
SR Electronic
T1 Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.02.20051359
DO 10.1101/2020.04.02.20051359
A1 Sinisalu, Lisanna
A1 Sen, Partho
A1 Salihović, Samira
A1 Virtanen, Suvi M.
A1 Hyöty, Heikki
A1 Ilonen, Jorma
A1 Toppari, Jorma
A1 Veijola, Riitta
A1 Orešič, Matej
A1 Knip, Mikael
A1 Hyötyläinen, Tuulia
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.04.02.20051359.abstract
AB OBJECTIVES Celiac disease (CD) is a systemic immune-mediated disorder with increased frequency in the developed countries over the last decades implicating the potential causal role of various environmental triggers in addition to gluten. Herein, we apply determination of perfluorinated alkyl substances (PFAS) and combine the results with the determination of bile acids (BAs) and molecular lipids, with the aim to elucidate the impact of prenatal exposure on risk of progression to CD in a prospective series of children prior the first exposure to gluten (at birth and at 3 months of age).METHODS We analyzed PFAS, BAs and lipidomic profiles in 76 plasma samples at birth and at 3 months of age in the Type 1 Diabetes Prediction and Prevention (DIPP) study (n=17 progressors to CD, n=16 healthy controls, HCs).RESULTS Plasma PFAS levels showed a significant inverse association with the age of CD diagnosis in infants who later progressed to the disease. Associations between BAs and triacylglycerols (TGs) showed different patterns already at birth in CD progressors, indicative of different absorption of lipids in these infants.DISCUSSION PFAS exposure may modulate lipid and BA metabolism, and the impact is different in the infants who develop CD later in life, in comparison to HCs. The results indicate more efficient uptake of PFAS in such infants. Higher PFAS exposure during prenatal and early life may accelerate the progression to CD in the genetically predisposed children.WHAT IS KNOWN Several observational studies have implicated a role of early life environmental triggers other than gluten in the development of CD. This is supported by the findings showing dysregulation of lipids already prior to the first introduction of gluten.WHAT IS NEW HERE We show that prenatal exposure to perfluorinated compounds is associated with changes in the lipid metabolism, most likely through the bile acids, and that a high exposure during prenatal and early life may accelerate the progression to CD in the genetically predisposed children.TRANSLATIONAL IMPACT Exposure to environmental chemicals may impact the rate of progression to CD and should be assessed as a potential risk factor of CD in larger clinical cohort settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funding from Vetenskapsrådet (to T.H.; grant no. 2016-05176) and Formas (to T.H. and M.O.; grant no. 2019-00869). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe lipidomics data sets and the clinical metadata generated in this study are available from MetaboLights, under accession number MTBLS729.